The FDA approved Takeda Pharmaceuticals' oveporexton (Orzeyful) for narcolepsy type 1, the first orexin receptor 2-selective agonist cleared for the condition. Two 12-week trials with 273 adults showed improved wakefulness, reduced cataplexy, and gains across sleep paralysis, hallucinations, and disrupted nighttime sleep. The oral 2 mg twice-daily tablet restores deficient orexin activity rather than masking symptoms.
The FDA approved Takeda Pharmaceuticals' oveporexton (Orzeyful) for narcolepsy type 1, the first orexin agonist cleared to treat the full range of symptoms in adults.
"For too long, people with narcolepsy type 1 have had to manage a complex, lifelong neuropsychiatric condition with treatments that only address pieces of it," Tiffany R. Farchione, MD, director of the Division of Psychiatry within the FDA's Center for Drug Evaluation and Research, said. "This new drug is the first medicine that impacts the underlying biology of the disease, treating narcolepsy type 1 as a whole."
The approval was based on two 12-week randomized, double-blind, placebo-controlled trials enrolling 273 adults with narcolepsy type 1. Patients taking oveporexton 2 mg showed improvements in their ability to stay awake during the day and reported substantially less daytime sleepiness. Treatment also produced significant reductions in cataplexy episodes and improvements across sleep paralysis, hallucinations, and disrupted nighttime sleep. The most common adverse effects were insomnia, increased urinary frequency, urgency to urinate, and increased saliva production. Discontinuation rates were low, and more than 95 percent of participants who completed the initial studies enrolled in the ongoing long-term extension.
Oveporexton is an oral 2 mg tablet taken twice daily. It works by selectively activating the orexin receptor 2 to restore deficient orexin activity — the underlying cause of narcolepsy type 1, which affects an estimated 1 in 2,000 people in the United States. The drug should not be used concurrently with strong CYP3A inhibitors. Safety and effectiveness have not been established in patients under 18 years of age.
The approval follows Breakthrough Therapy Designation and Priority Review granted in February 2026. Oveporexton has been recommended for scheduling under the Controlled Substances Act, with a Drug Enforcement Administration decision pending.
Narcolepsy type 1 is caused by the loss of brain cells that produce orexin, a chemical messenger regulating wakefulness, sleep, and muscle tone. Current treatments — stimulants and sodium oxybates — carry risks of misuse and leave many patients still feeling sleepy. Oveporexton directly activates the same receptor the body's own orexin would normally stimulate, addressing the disease mechanism rather than masking symptoms.
The approval gives Takeda a first-mover advantage in the orexin agonist class. Competitors Alkermes and Eli Lilly, which acquired Centessa in March 2026, are testing similar drugs in narcolepsy type 2 and idiopathic hypersomnia. The broader ambition for the class extends to neuropsychiatric conditions involving sleepiness and fatigue, including Alzheimer's disease and depression.
The approval is a major commercial milestone for Takeda, which spent more than a decade developing orexin agonists after an earlier candidate failed on liver toxicity concerns. Investors will watch the DEA scheduling decision and the drug's launch trajectory as the first entrant in a potentially large new market for sleep-disorder treatments.
This article is for informational purposes only and does not constitute investment advice.
